BMGF – Gates Foundation  [to 27 January 2018]
JANUARY 26, 2018
Investing in Africa: the EU and Bill & Melinda Gates Foundation commit a further €100 million
BRUSSELS (25 January 2018) – The Bill & Melinda Gates Foundation today announced their commitment to contribute to the EU’s External Investment Plan.
The Gates Foundation will contribute $50 million (€40.9 million) in financing, as well as an additional $12.5 million (€10.2 million) in technical assistance, to investment projects in the health sector in Africa through the EU’s framework to improve sustainable investments in Africa.       This pooling of resources is designed to encourage additional private investment towards achieving the Sustainable Development Goals, and will allow successful projects to be scaled up more rapidly. The European Commission welcomes this strong support to its efforts towards sustainable development in Africa, and will match this contribution with another €50 million…

JANUARY 26, 2018
Initiative Announced to End Malaria in Central America and the Dominican Republic
Inter-American Development Bank, Bill & Melinda Gates Foundation and Carlos Slim Foundation to endorse five-year initiative
DAVOS, Switzerland – The Inter-American Development Bank (IDB), the Bill & Melinda Gates Foundation and the Carlos Slim Foundation today announced an initiative to support seven Central American countries and the Dominican Republic in taking the final steps necessary to eliminate malaria in their territories. The Regional Malaria Elimination Initiative (RMEI) will bring $83.6 million in new funds, and is expected to leverage over $100 million in domestic financing and $39 million of existing donor resources across the region by 2022 to ensure malaria remains a top health and development priority despite dwindling numbers of cases. The funding will serve to close the technical and financing gaps to support and execute country elimination plans in Belize, Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Nicaragua and Panama…

European Medicines Agency  [to 27 January 2018]
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2018
…The Committee recommended granting a marketing authorisation for Shingrix (recombinant, adjuvanted Herpes zoster vaccine), a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in adults 50 years of age or older….

Human medicines: highlights of 2017
92 medicines recommended for approval, including 35 with a new active substance …
Gavi [to 27 January 2018]
25 January 2018
Orange, Gavi and Côte d’Ivoire Ministry of Health join forces to boost child immunisation
The mobile phone project “M-Vaccin Côte d’ Ivoire” will raise awareness of immunisation among parents and communities to increase vaccine coverage in regions with the lowest coverage.
Davos, 25 January 2018 – Orange SA and Gavi, the Vaccine Alliance, will enter into a partnership with the Côte d’Ivoire Ministry of Health to increase immunisation rates in the regions and districts with the lowest vaccine coverage, it was announced at the World Economic Forum today.
The “M-Vaccin Côte d’Ivoire” project uses Orange mobile technology to inform parents about the importance of vaccination by sending text and voice messages in the local language. Targeted messages will also help ensure parents don’t miss immunisation sessions by reminding them of their children’s schedule and dates.
“This new partnership is truly innovative and important for the children of Côte d’Ivoire,” explained Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “Parents often do not receive enough information about the importance of immunisation because they live a long way from health centres or in hard-to-reach places. These voice and text messages should therefore have a significant impact and lead to an increase in vaccine coverage.”…

Global Fund [to 27 January 2018];&country=
Lombard Odier and the Global Fund Join Forces to Expand Private Investment In Global Health
26 January 2018
Lombard Odier and the Global Fund are pleased to announce a strategic partnership to rethink traditional approaches to investment and philanthropy to make it easier for more people to contribute to the fight against some of the world’s most pressing health challenges. Together they will create innovative solutions that allow investors to meet both their goals of doing well financially and doing good socially…
Lombard Odier and the Global Fund have come together in their belief that private sector investment is a vital resource that needs to be better employed to support the sustainable development agenda – particularly ending HIV, TB and malaria as epidemics, and building strong, resilient systems for health. The demand for capital is high. A funding gap of US$20 billion was identified for 2017-2019 to implement approved strategies to fight the three diseases in countries where the Global Fund invests, so every extra dollar can help to maximize the positive impact of the Global Fund partnership. Increased funding can also support innovative, evidence-based approaches that generate greater impact for communities affected by the diseases…

Global Fund and Partners Launch HER
24 January 2018
The Global Fund to Fight AIDS, Tuberculosis and Malaria and partners pledged support for HER – HIV Epidemic Response – an initiative to build private sector support for programs that address HIV in 13 African countries where adolescent girls and young women face disproportionate risk.
JEE Alliance  [to 27 January 2018]
Alliance successes in 2017 and an update on 2018
The year 2017 was the first full year of the work of the JEE Alliance. During the year, 15 new members joined the Alliance, contributing the wealth of expertise and experience. There are now 68 members…
NIH  [to 27 January 2018]
January 24, 2018
15 years later, PEPFAR continues to save lives
— NIAID experts highlight federal program’s unprecedented impact on HIV pandemic.

Study links gut-homing protein levels with HIV infection risk, disease progression
January 24, 2018 — NIH clinical trial is testing antibody against the protein in people with HIV.

NIH begins large HIV treatment study in pregnant women
January 24, 2018 — Clinical trial will compare three antiretroviral drug regimens.

NIH to launch genome editing research program
January 23, 2018 — Somatic Cell Genome Editing aims to develop tools for safe and effective genome editing in humans.

Flu infection study increases understanding of natural immunity
January 23, 2018 — Findings illustrate role of specific antibodies.
PATH  [to 27 January 2018]
Press release | January 24, 2018
India-made rotavirus vaccine achieves World Health Organization prequalification
ROTAVAC® will now be available for procurement by United Nations agencies and Gavi, the Vaccine Alliance, for use in low-resource countries
New Delhi, January 24, 2018—PATH applauds Indian vaccine manufacturer Bharat Biotech for receiving prequalification from the World Health Organization (WHO) for their oral rotavirus vaccine, ROTAVAC. As a partner in the development of ROTAVAC, PATH worked with the Indian Department of Biotechnology, the Society for Applied Studies, and Bharat Biotech on the clinical trials that demonstrated the safety and efficacy of the vaccine…

UNAIDS [to 27 January 2018]
22 January 2018
How do investment vehicles and innovations work together to deliver better health care?
UNAIDS, ICV, Johnson & Johnson, BD and the Center for Global Health and Diplomacy are hosting a forum entitled Transformational Aid for Development in order to create connections for scaling up innovations and investments for health and to reach vulnerable populations…

UNICEF  [to 27 January 2018]
24 January 2018
More action needed to improve security and humanitarian access in Myanmar if Rohingya children are to return safely – UNICEF
COX’S BAZAR, Bangladesh, 24 January 2018 –  Improved security and unimpeded humanitarian access in Myanmar are essential before Rohingya children can be returned from Bangladesh, UNICEF Deputy Executive Director Justin Forsyth said today.

Statement by Geert Cappelaere, UNICEF Regional Director for the Middle East and North Africa, on Syrian children freezing to death while crossing from Syria to Lebanon
AMMAN, 20 January 2018- “It is tragic that at least 12 Syrians including two children died in Eastern Lebanon near the Masna’ border crossing with Syria.”

At least one in four children in Iraq impacted by conflict and poverty
BAGHDAD/AMMAN, 19 January 2018 – “Iraq today hosts one of UNICEF’s largest operations in the world, responding with humanitarian and development assistance to the needs of the most vulnerable girls and boys across the country.

Wellcome Trust  [to 27 January 2018]
News / Published: 25 January 2018
What our new strategy means for the Public Engagement Fund
We’ve developed an ambitious new strategy for our public engagement work and, as a result, we are making some changes to the Public Engagement Fund.
When we launched the Public Engagement Fund in January 2017 we said that the fund would evolve – as we learned from its implementation, and to reflect Wellcome’s changing vision.
After the changes, funding will still be open to anyone with a great project for engaging the public in Wellcome’s mission of improving health…

News / Published: 22 January 2018
New Wellcome office in Berlin will bolster global partnerships
News / Published: 22 January 2018
Wellcome is planning to open a small office in the German capital later this year so that we can work more closely with our international partners on shared priorities…

The Wistar Institute   [to 27 January 2018]
Press Releases
Wistar’s David Weiner, Ph.D., Named President of the International Society for Vaccines
PHILADELPHIA—(Jan. 25, 2018)—The Wistar Institute is pleased to announce David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute, and the W.W. Smith Charitable Trust Professor in Cancer Research, has been appointed President of the International Society for Vaccines (ISV), an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines.
“As I begin my service as ISV President, it is important to keep in mind that our overarching goals and focus remains the same: serve all of our members and continue to build the society and ‘lift all boats’ in vaccine research around the globe,” Weiner said. “In this regard, we extend our hand and encourage all members to be engaged and energized, and to take an active role in this society-your society.”…

IFPMA   [to 27 January 2018]
24 January 2018
The African Global Health Leaders Fellowship launched to support the future of health in Africa
Geneva, 24 January 2018│ The Centre on Global Health Security at Chatham House, the Global Health Centre at the Graduate Institute and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced yesterday the establishment of the 2018-2019 African Global Health Leaders Fellowship.
Sub-Saharan African countries have undergone unprecedented transformation and change in the last decade, including constant economic growth, a growing middle class, a healthier, more productive and increasingly more educated and skilled workforce and increased political stability. Although many challenges remain, recognition must be given to the huge advances that have been made.
To mark the occasion, the three signing partners invited emerging leaders and fellows of the West African Global Health Leaders Fellowship ─ the predecessor of the new fellowship, to discuss the achievements and challenges across the continent, including the most promising approaches for improving healthcare systems and the realisation of Universal Health Coverage (UHC).
The fellowship supports the development of the next generation of public health leaders in Africa. The objective is to help fellows from Africa develop the knowledge, insight and skills to work within their own countries to formulate and implement evidence-based policy and to serve as the next generation of leaders. It builds skills in leadership, policy analysis and formulation, as well as global health diplomacy…

Industry Watch   [to 27 January 2018]
:: World Health Organization Grants Prequalification to Bharat Biotech’s Rotavirus Vaccine, ROTAVAC®
NEW DELHI–(BUSINESS WIRE)–Bharat Biotech today announced that the World Health Organization (WHO Geneva) has awarded prequalification to the developing world’s first rotavirus vaccine, ROTAVAC®…

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at:
2018 Antimicrobial Resistance Benchmark
Access to Medicine Foundation
January 2018 :: 185 pages
The Antimicrobial Resistance Benchmark provides the first independent assessment of how pharmaceutical companies are responding to AMR. The 30 companies in scope include those
with the largest R&D divisions, the largest market presence, and specific expertise in developing critically needed medicines and vaccines. The goal of the Antimicrobial Resistance Benchmark is
to guide and incentivise such companies to adopt and implement effective actions for tackling AMR. It highlights where good ideas for limiting AMR are being implemented and where action
is still required. The AMR Benchmark is independently funded by UK AID and the Dutch Ministry of Health, Welfare and Sport.

Key Findings
:: There are 28 antibiotics for high-priority pathogens in late stages of development. However, only two of these are supported by plans to ensure the successful candidate can be made accessible and used wisely once it reaches the market.

:: Nearly half of companies evaluated are involved in efforts to track patterns in antibiotic drug resistance, with AMR surveillance programmes running in 147 countries. Pneumonia is the most widely-tracked infection.

:: Eight companies are setting limits on the levels of antibiotics that can be released into the environment in wastewaters at their antibiotic manufacturing facilities. Yet no company publishes what is released in practice.
:: Four companies are taking steps to separate sales agents’ bonuses from the volume of antibiotics they sell. GSK and Shionogi have fully separated the two globally, Pfizer is piloting that approach in certain territories, and Novartis is taking steps toward adjusting its sales teams incentives.

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at:

Systematic review of electronic surveillance of infectious diseases with emphasis on antimicrobial resistance surveillance in resource-limited settings

American Journal of Infection Control
February 2018 Volume 46, Issue 2, p123-244

Major Articles
Systematic review of electronic surveillance of infectious diseases with emphasis on antimicrobial resistance surveillance in resource-limited settings
Pinyo Rattanaumpawan, Adhiratha Boonyasiri, Sirenda Vong, Visanu Thamlikitkul
Published online: October 10, 2017
Electronic surveillance of infectious diseases involves rapidly collecting, collating, and analyzing vast amounts of data from interrelated multiple databases. Although many developed countries have invested in electronic surveillance for infectious diseases, the system still presents a challenge for resource-limited health care settings.
We conducted a systematic review by performing a comprehensive literature search on MEDLINE (January 2000-December 2015) to identify studies relevant to electronic surveillance of infectious diseases. Study characteristics and results were extracted and systematically reviewed by 3 infectious disease physicians.
A total of 110 studies were included. Most surveillance systems were developed and implemented in high-income countries; less than one-quarter were conducted in low-or middle-income countries. Information technologies can be used to facilitate the process of obtaining laboratory, clinical, and pharmacologic data for the surveillance of infectious diseases, including antimicrobial resistance (AMR) infections. These novel systems require greater resources; however, we found that using electronic surveillance systems could result in shorter times to detect targeted infectious diseases and improvement of data collection.
This study highlights a lack of resources in areas where an effective, rapid surveillance system is most needed. The availability of information technology for the electronic surveillance of infectious diseases, including AMR infections, will facilitate the prevention and containment of such emerging infectious diseases.

Middle East respiratory syndrome coronavirus transmission among health care workers: Implication for infection control

American Journal of Infection Control
February 2018 Volume 46, Issue 2, p123-244

Middle East respiratory syndrome coronavirus transmission among health care workers: Implication for infection control
Sarah H. Alfaraj, Jaffar A. Al-Tawfiq, Talal A. Altuwaijri, Marzouqa Alanazi, Nojoom Alzahrani, Ziad A. Memish
Published online: September 25, 2017

Immunization Practices of U.S. Obstetrician/Gynecologists for Pregnant Patients

American Journal of Preventive Medicine
February 2018 Volume 54, Issue 2, p157-324

Research Articles
Immunization Practices of U.S. Obstetrician/Gynecologists for Pregnant Patients
Sean T. O’Leary, Laura E. Riley, Megan C. Lindley, Mandy A. Allison, Lori A. Crane, Laura P. Hurley, Brenda L. Beaty, Michaela Brtnikova, Margaret Collins, Alison P. Albert, Allison K. Fisher, Angela J. Jiles, Allison Kempe
Published online: December 12, 2017

Nativity Disparities in Human Papillomavirus Vaccination Among U.S. Adults

American Journal of Preventive Medicine
February 2018 Volume 54, Issue 2, p157-324

Nativity Disparities in Human Papillomavirus Vaccination Among U.S. Adults
…few studies have explored whether vaccination differences exist by nativity status. Vaccination disparities have the potential to exacerbate HPV-related cancer disparities in the long term if left unaddressed. Therefore, the authors investigated whether there were significant differences in HPV vaccination initiation (one or more doses) and completion (three or more doses) between U.S.-born and foreign-born men and women.
Ashley E. Pérez, Madina Agénor, Kristi E. Gamarel, Don Operario
Published online: December 11, 2017